Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Dr Reddy’s Sees Tocilizumab Clear Phase I
Indian Firm’s Biosimilar Rival To Actemra/RoActemra Moves Into Phase III Trials
Dec 21 2022
•
By
David Wallace
Dr Reddy’s has successfully completed a Phase I study for tocilizumab • Source: Shutterstock
More from Biosimilars
More from Products